Surefire collects $16.4M to expand cancer-drug catheter biz

Colorado startup Surefire Medical picked up $16.4 million from 30 investors to support expansion of its operations, according to a report in the Denver Business Journal. The four-year-old startup develops cancer-drug delivering catheters, which are designed to administer treatment directly to tumors through a process called chemoembolization. The device gained FDA approval in 2011 and a CE mark this year. The Journal reports that Surefire offered to sell as much as $21.3 million in equity. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.